Form 4: Corcept Therapeutics Executive William Guyer Executes Stock Option and Sells Shares

William Guyer, Chief Development Officer of Corcept Therapeutics, exercised stock options and sold shares on May 16, 2025, according to a recent SEC filing.

Summary

• On May 16, 2025, William Guyer, the Chief Development Officer of Corcept Therapeutics, exercised a stock option to purchase 32,262 shares of common stock at a price of $21.65 per share.
• Simultaneously, Guyer sold 32,262 shares of common stock at a weighted average price of $74.1744 per share, with individual sale prices ranging from $73.94 to $74.66.
• These transactions were executed under a pre-arranged 10b5-1 trading plan adopted on November 27, 2024.
• Following these transactions, Guyer directly owns 5,487 shares of common stock and holds options for 410,000 shares.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of insider trading activity. The transactions were conducted under a pre-arranged plan, suggesting no particular bullish or bearish sentiment.

Industry Context

This filing is a routine disclosure of insider transactions. It's common for executives to exercise stock options and sell shares, especially under pre-arranged trading plans like 10b5-1 plans, which allow insiders to trade without being accused of acting on non-public information.

Comparison to Industry Standards

• Executive compensation packages often include stock options as a way to align management's interests with those of shareholders.
• The use of 10b5-1 trading plans is a standard practice among corporate executives to avoid accusations of insider trading.
• The size and frequency of these transactions are typical for executives at publicly traded companies.

Stakeholder Impact

• The transaction could have a minor impact on shareholders due to the change in ownership.
• The sale of shares by an executive could be perceived negatively by some investors, although the 10b5-1 plan mitigates this concern.

Key Dates

Keywords

Corcept Therapeutics, William Guyer, Stock Options, SEC Form 4, Insider Trading, CORT, 10b5-1 plan, Chief Development Officer